Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH — Clinical Trial Site

47 Registered trials

25 Currently recruiting

Organisation

Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH

Location

Regensburg, Germany

Identifier

ORG-100019988

Address

Romanstrasse 93, Neuhausen-Nymphenburg, 80639, Germany

Departments

-
#2053:Onkologie und Hämatologie
049004_Klinik für Kinder- und Jugendmedizin
2516: Klinik für Onkologie und Hämatologie Studienzentrum Onkologie
Abteilung für Onkologie und Hämatologie
Abteilung Rheumatologie
Clinic for Oncology and Hematology
Hämatologie/Onkologie
Innere Medizin I
Innere Medizin, Haematologie
Kinder-Uni-Klinik Ostbayern (KUNO); KLINIK UND POLIKLINIK FÜR KINDER- UND JUGENDMEDIZIN
Klinik für Onkologie und Haematologie
Klinik für Onkologie und Hämatologie
Klinik für Onkologie und Hämatologie;
Klinik St. Hedwig - Klinik für Frauenheilkunde und Geburtshilfe
Krankenhaus Barmherzige Brüder Klinik für Onkologie und Hämatologie
Krankenhaus Barmherzige Brüder Regensburg
Kuno Klinik St. Hedwig Kinder Jugendmedizin Steinmetzstr. 1-3
Oncology and hematology
Onkologie und Hämatologie
Studienzentrum Klinik für Onkologie und Hämatologie

Clinical trials at this site (47)

Search interface

Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending

2025-523947-36-00 Sub-study 5: Unresectable Pleural Mesothelioma (Volrust 4
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting

2025-522046-42-00 Colonic disease 5 2026-03-24
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
adIVO Recruiting

2024-520219-42-00 ivosidenib maintenance after SOC adjuvant chemotherapy 10 2025-11-18
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting

2024-512849-17-00 Systemic Autoimmune Rheumatic Diseases associated Inter 5 2025-11-14
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Maternal oxygen therapy during pregnancy for unborn babies with underdeveloped structures on the left side of the heart Recruiting

2024-512679-11-00 unborn baby with developmental disorder of the left sid 5 2025-04-25
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Acute myeloid leukemia 4 2024-04-07
Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting

2023-504141-31-00 Metastatic HR positive, HER2 negative breast cancer 4 2024-01-17
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone:… Recruiting

2023-503558-10-00 oligometastatic pancreatic cancer 5 2023-10-13
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 Antibody Recruiting

2023-509278-41-00 Early Stage Follicular LymphOma 5 2022-07-04
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17